Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile \textit{in vivo}

Jun-Yan Liu, See-Hyoung Park, Christophe Morisseau, et al.

\textit{Mol Cancer Ther} 2009;8:2193-2203. Published OnlineFirst August 11, 2009.

Updated version Access the most recent version of this article at: doi:10.1158/1535-7163.MCT-09-0119

Supplementary Material Access the most recent supplemental material at: http://mct.aacrjournals.org/content/suppl/2009/08/19/1535-7163.MCT-09-0119.DC1.html

Cited Articles This article cites by 54 articles, 14 of which you can access for free at: http://mct.aacrjournals.org/content/8/8/2193.full.html#ref-list-1

Citing articles This article has been cited by 1 HighWire-hosted articles. Access the articles at: http://mct.aacrjournals.org/content/8/8/2193.full.html#related-urls

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.
Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo

Jun-Yan Liu, See-Hyoung Park, Christophe Morisseau, Sung Hee Hwang, Bruce D. Hammock, and Robert H. Weiss

1Department of Entomology, 2Cancer Research Center, 3Comparative Pathology Graduate Group, and 4Division of Nephrology, Department of Internal Medicine, University of California, Davis, California; and 5U.S. Department of Veterans’ Affairs Medical Center, Sacramento, California

Abstract
The advent of multikinase inhibitors targeting the vascular endothelial growth factor (VEGF) receptor has revolutionized the treatment of highly angiogenic malignancies such as renal cell carcinoma. Interestingly, several such inhibitors are commercially available, and they each possess diverse specific beneficial and adverse effect profiles. In examining the structure of sorafenib, it was hypothesized that this compound would possess inhibitory effects on the soluble epoxide hydrolase, an enzyme with pleiotropic effects on inflammation and vascular disease. We now show that sorafenib but not another VEGF receptor targeted inhibitor sunitinib is a potent inhibitor of the human soluble epoxide hydrolase in vitro ($K_i = 17 \pm 4$ nmol/L). Furthermore, sorafenib causes the expected in vivo shift in oxylipid profile resulting from soluble epoxide hydrolase inhibition, evidence of a reduction in the acute inflammatory response. Lipopolysaccharide-induced hypotension was reversed with sorafenib but not sunitinib treatment, suggesting that soluble epoxide hydrolase inhibition accounts for at least part of the anti-inflammatory effect of sorafenib. The pharmacokinetic studies presented here in light of the known potency of sorafenib as a soluble epoxide hydrolase inhibitor indicate that the soluble epoxide hydrolase will be largely inhibited at therapeutic doses of sorafenib. Thus, it is likely that soluble epoxide hydrolase inhibition contributes to the beneficial effects from the inhibition of the VEGF receptor and other kinases during treatment with sorafenib. [Mol Cancer Ther 2009;8(8):2193–203]

Introduction
With the advent of more complete knowledge of the molecular biology of cancer, new therapies have recently been designed that target mechanisms by which the disease escapes standard therapy. For example, the multikinase and vascular endothelial growth factor (VEGF) receptor inhibitors, such as sorafenib and sunitinib (1, 2), interrupt the pathway by which angiogenesis becomes established and promulgated, resulting in inadequate nourishment of metastatic disease, thereby leading to a higher degree of treatment success. In certain malignancies such as kidney cancer, whose mechanism of oncogenesis generally involves disrupted hypoxia pathways and thus is highly angiogenic, these agents have had the effect of revolutionizing treatment.

Upon viewing the recently described X-ray crystal structure of B-Raf complexed with sorafenib (3), we noted a structural similarity between this drug (Fig. 1A) and the class of urea-based compounds (Fig. 1B) that inhibit the soluble epoxide hydrolase (4). The soluble epoxide hydrolase converts epoxyeicosatrienoic acids to the less active dihydroxyeicosatrienoic acids (5). The epoxyeicosatrienoic acids have been shown to be vasodilators in various animal models (6–10) and play an important role in regulation of blood pressure as well as control and prevention of heart disease (11–14). In addition, epoxyeicosatrienoic acids are potentially anti-inflammatory through mediating the nuclear factor κB and IκB kinase system (15–17). The soluble epoxide hydrolase inhibitors have been shown to stabilize the epoxyeicosatrienoic acid levels and thus have beneficial effects on hypertension (18), nociception (19), atherosclerosis (20), and inflammation (21) through increasing endogenous levels of epoxyeicosatrienoic acids and other lipid epoxides. Thus, we asked whether sorafenib possesses soluble epoxide hydrolase inhibitory activity and, consequently, whether this effect influences the known beneficial properties or adverse effects of this drug.

Although there are several VEGF receptor inhibitors commercially available (2), there exist differences in effect profiles for the various clinically available agents. Although there are minimal published studies comparing sunitinib to sorafenib in renal cell carcinoma (22), with the one available study showing a greater frequency of gastrointestinal symptoms with sunitinib (23), there is an ongoing National Cancer Institute clinical trial to attempt to address this issue.
Sorafenib Is an Inhibitor of Soluble Epoxide Hydrolase

( ClinicalTrials.gov Identifier, NCT00326898). In an attempt to explain differences in VEGF receptor inhibitor treatment outcomes as well as adverse events, we have examined the soluble epoxide hydrolase inhibitory properties of this renal cell carcinoma therapeutic.

We now show that sorafenib but not another clinically available VEGF receptor inhibitor sunitinib possesses powerful soluble epoxide hydrolase inhibitory activity. Although the soluble epoxide hydrolase inhibition showed by sorafenib shows the expected alteration in oxid lipin profile in mice, such activity does not contribute to kinase inhibition or sorafenib-induced cytotoxicity shown by the VEGF inhibitors. Thus, sorafenib, in addition to its advantageous effects on tyrosine kinases, may also result in salutary effects on hypertension, inflammation, or nociception based on its property of soluble epoxide hydrolase inhibition.

Materials and Methods

Materials

The extracellular signal-regulated kinase (ERK), phospho-ERK, and β-actin antibodies were from Sigma, and the Poly (ADP-ribose) polymerase (PARP), VEGF receptor, and p-VEGF receptor were from Cell Signaling. Goat anti-mouse and goat anti-rabbit horseradish peroxidase-conjugated immunoglobulin G were obtained from Bio-Rad, and ECL Western Blotting Detection Reagents were obtained from Amersham Biosciences. Recombinant human soluble epoxide hydrolase enzymes were produced in a baculovirus expression system and purified by affinity chromatography (24, 25).

Figure 1. Structural similarity of sorafenib (A), dCP2PU (B), and t-AUCB (C). B and C are potent soluble epoxide hydrolase inhibitors; refs. 33, 54). The compound B (dCP2PU) is 1-(3,4-dichlorophenyl)-3-(4-phenoxyphenyl)urea and C (t-AUCB) is trans-4-14-(3-adamantan-1-yl-ureido)-cyclohexyloxy)-benzoic acid, respectively.

Cell Lines

ACHN and A498 human renal cell carcinoma cells (from American Type Culture Collection) were maintained in MEM 1× media supplemented with 10% fetal bovine serum, 2 mmol/L L-glutamine, 1 mmol/L sodium pyruvate, 0.1 mmol/L nonessential amino acid, and 0.75% sodium bicarbonate at 37°C in a humidified incubator containing 5% CO₂ in air.

Measurement of Soluble Epoxide Hydrolase Inhibition

Protein concentration was quantified using the Pierce bicinchoninic acid assay with bovine serum albumin as calibrating standard. The IC₅₀ were determined by a fluorescent assay using cyano(6-methoxy-naphthalen-2-yl)methyl trans-[3-(phenoxymyr-2-yl)methyl] carbonate as a fluorescent substrate (26). Human soluble epoxide hydrolase was used at a concentration of 1 nmol/L that gave linear generation of product with time and protein concentration. Human soluble epoxide hydrolase was incubated with inhibitors for 5 min Bic-TRIS/HCl buffer (25 mmol/L; pH 7.0) containing 0.1 mg/mL of bovine serum albumin at 30°C before substrate introduction ([S] = 5 μmol/L). Activity was measured by determining the appearance of the 6-methoxy-2-naphthaldehyde with an excitation wavelength of 330 nm and an emission wavelength of 465 nm for 10 min. Assays were done in triplicate. IC₅₀ is the concentration of inhibitor that reduces enzyme activity by 50%. IC₅₀ was determined by regression of at least five datum points, with a minimum of two points in the linear region of the curve on either side of the IC₅₀. Results are presented as the average ± SD of three separate measurements.

Kinetic Assay Conditions

Dissociation constants were determined following the method described by Dixon (27) for competitive tight binding inhibitors, using [³H]-1,3-diphenyl-trans-propene oxide (t-DPPO) as substrate (28). Sorafenib showed no inhibition between 0 and 50 nmol/L. For sultinib [0–25 nmol/L for 12-(3-adamantan-1-yl-ureido)-dodecanolic acid (AUDA); 0–5 nmol/L for trans-4-[3-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (t-AUCB); 0–200 nmol/L for 1-trifluoromethoxyphenyl-3-(1-acetyl)piperidin-4-yl)urea (TIPAU); 0–50 nmol/L for 1-trifluoromethoxyphenyl-3-(1-methylsulfonyl)piperidin-4-yl)urea (TUPS) was incubated in triplicate for 5 min in sodium phosphate buffer (pH 7.4) at 30°C with 100 μL of the enzyme (1 nmol/L of human soluble epoxide hydrolase). Substrate (3.6 < [S] < 30 μmol/L) was then added. Velocity was measured as described (28). For each substrate concentration, the plots of the velocity as a function of the inhibitor concentration allow the determination of an apparent inhibition constant (Kapp; ref. 27). The plot of these Kapp as a function of the substrate concentration allows the determination of K₁ when [S] = 0. Results are presented as average ± SE of K₁ calculation.

Molecular Modeling

Molecular modeling was done using BioMedCAChe 5.0 software (Fujitsu Computer Systems Corporation). The atomic coordinates of the crystal structure of human soluble
Table 1. Structure and inhibition potency against the murine and human soluble epoxide hydrolases

<table>
<thead>
<tr>
<th>Inhibitors</th>
<th>Name</th>
<th>Inhibition of the murine sEH IC$_{50}$ (nmol/L)</th>
<th>Inhibition of the human sEH IC$_{50}$ (nmol/L)</th>
<th>$K_i$ (nmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sorafenib</td>
<td>30 ± 3</td>
<td>12 ± 2</td>
<td>17 ± 4</td>
<td></td>
</tr>
<tr>
<td>Sunitinib</td>
<td>17,000 ± 1,000</td>
<td>55,000 ± 1,000</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Dasatinib</td>
<td>27,000 ± 2,000</td>
<td>6,500 ± 500</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>AUDA</td>
<td>8 ± 1</td>
<td>3 ± 1</td>
<td>6.9 ± 0.2</td>
<td></td>
</tr>
<tr>
<td>t-AUCB</td>
<td>4 ± 1</td>
<td>2 ± 1</td>
<td>1.5 ± 0.2</td>
<td></td>
</tr>
<tr>
<td>TPAU</td>
<td>44 ± 3</td>
<td>12 ± 3</td>
<td>57 ± 6</td>
<td></td>
</tr>
<tr>
<td>TUPS</td>
<td>11 ± 1</td>
<td>3 ± 1</td>
<td>14 ± 4</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ND, not determined; sEH, soluble epoxide hydrolase.
epoxide hydrolase complexed with the soluble epoxide hydrolase inhibitor were retrieved from Protein Data Bank (entry 1ZD3; ref. 29). The soluble epoxide hydrolase inhibitor was removed from the active site, and sorafenib was manually docked into the ligand-binding pocket by superposition with the parent molecule soluble epoxide hydrolase inhibitor. The ligand and the amino acid residues within 8.0 Å from the ligand were minimized on molecular modeling geometry.

Bromide (MTT) Assay
A 200 μL aliquot of cells (1 × 10^5 cells in quiescent media) was added to a 96-well plate and incubated for 18 h at 37°C in a humidified incubator containing 5% CO₂ in air. After incubation, the test compounds at the indicated concentration were added into each well for 48 h. Control cultures were treated with DMSO. After incubation, a 20 μL MTT solution (5 mg/mL in phosphate buffer) was added to each well, and the incubation continued for 4 h, after which time the solution in each well was carefully removed. The blue crystalline precipitate in each well was dissolved in DMSO (200 μL). The visible absorbance at 560 nm of each well was quantified using a microplate reader.

Caspase Assay
The CaspACE assay kit (Promega) was used to measure the protease activity of caspase-1 (interleukin 1β converting enzyme) and caspase-3 (32-KD putative cysteine protease), per the manufacturer’s instructions. Briefly, 2 × 10^5 cells per 10-cm dish were treated as described in the text. Positive control cultures were treated with 4 μM Camptothecin. The cells were harvested and washed, and equal protein quantities were incubated with the Asp-Glu-Vel-Asp p-nitroanilide (DEVD-pNA) caspase-3 substrate in Caspase Assay Buffer. The plates were covered with parafilm and incubated at 37°C overnight. Color development was measured at 405 nm.

Pharmacokinetics Protocol
Male Swiss-Webster mice (8 wk) were purchased from Charles River Laboratories, and experiments were done according to protocols approved by the Animal Use and Care Committee of University of California-Davis. Sorafenib tosylate (1 mg) was suspended in 1 mL trioleine and then strongly mixed on a mini vortexer for 5 min. Blood (10 μL) was collected from the tail vein using a pipette tip rinsed with 7.5% EDTA (K₃) at 0, 0.5, 1, 1.5, 2, 4, 6, 8, and 24 h after oral dosing with the inhibitor. The blood samples were prepared and analyzed according to the methods detailed in our previous study (30). Sorafenib was detected by negative model electrospray ionization tandem quadrupole mass spectrometry in multiple reaction-monitoring mode, with the precursor and dominant daughter ions of 463.0 and 193.8, respectively.

Measurement of Blood Pressure
Sorafenib and the soluble epoxide hydrolase inhibitor t-AUCB were dissolved in trioleine containing 10% ethanol and 10% polyethylene glycol (average molecular weight, 400; polyethylene glycol 400) to give a clear solution, where-as sunitinib gave a suspension in the same formulation solution. Male, Swiss Webster mice (8 wk) were randomly assigned to be injected i.p. with lipopolysaccharide (LPS; 10 mg/kg body weight) and immediately orally administered with sorafenib tosylate (20 mg/kg body weight, equal to 30 μmol/kg), sunitinib malate (17 mg/kg body weight, equal to 30 μmol/kg), or t-AUCB (1 mg/kg body weight, equal to 2.5 μmol/kg), respectively. Animals receiving oral gavage of trioleine containing 10% ethanol and 10% polyethylene glycol 400 immediately after i.p. injection of LPS or saline served as positive or negative controls, respectively. Systolic blood pressure was determined before and 24 h after treatment with noninvasive tail cuff methods using a CODA6 system (Kent Scientific Co.). For each measurement set, three acclimation cycles and 25 data cycles were used. The reported systolic blood is presented as a mean of at least five cycles of the measurement set. If the systolic blood pressure was under the detection limit, we recorded it as the detection limit (60 mmHg) for further analysis.

Metabolite Profiling Analysis of Oxylipin
Another set of animals was assigned in random to be repeatedly treated as above described. Animals were sacrificed 24 h after drug treatment. Blood was collected to separate plasma for oxylipin analysis and cytokine assay as previous reported methods (30). Plasma samples were extracted for oxylipin analysis using the methods described in (30). Plasma oxylipin were measured using an Agilent 1200 Series HPLC (Agilent Technologies, Inc.) coupled with an Applied Biosystems 4000 QTRAP hybrid, triple-quadrupole mass spectrometry instrument (Applied Biosystems). The instrument was equipped with a linear ion trap and a Turbo V ion source and was operated in negative multiple reaction-monitoring mode. Plasma oxylipins were separated using a 2.1 × 150 mm Pursuit XRs-C18 5-μm column (Varian, Inc.) held at 40°C. The gradient
conditions are given in Supplementary Table S1. The injection volume was 10 μL, and the samples were kept at 10°C in the autosampler. The mass spectrometers were set with a negative electrospray mode with following parameters: Curtain gas, 20 psi; Ion gas (GS) 1, 50 psi; GS2, 30 psi; Ion spray voltage, −4,500 V; Collision gas, high; temperature, 400°C; interface heater, on; and declustering potential, −60 V. The collision energies used for CAD (−18 to −38 eV) varied

Conventional soluble epoxide hydrolase inhibitors of varying potency do not cause significant apoptosis or attenuate phosphorylation of ERK or VEGF receptor. A, ACHN and A498 cells were serum starved for 18 h and treated with vehicle (QM lane is serum-free quiescence media alone; vehicle is DMSO at 1 μL/mL), platelet-derived growth factor, PD98059 (10 μmol/L), sorafenib (10 μmol/L), and soluble epoxide hydrolase inhibitors (10 μmol/L) for 1 h. After incubation, all cells except quiescence media control were stimulated with platelet-derived growth factor (10 ng/mL) for 15 min. Cells were harvested and immunoblotted with phospho-ERK (202Tyr204Thr) or nonphosphorylated ERK, as indicated. β-Actin is a gel loading control. B, ACHN cells were treated as in A, except that the soluble epoxide hydrolase inhibitors were treated at three different doses, as indicated. C, ACHN cells were treated in 10% serum-containing complete media with vehicle (DMSO at 1 μL/mL), PD98059 (10 μmol/L), sorafenib (10 μmol/L), and soluble epoxide hydrolase inhibitors (10 μmol/L) for 24 and 48 h. After incubation, cells were harvested and immunoblotted with phospho-VEGF receptor, VEGF receptor, and PARP. PARP activation is indicated by the appearance of the lower–molecular weight cleavage product. β-Actin is a gel loading control.
according to molecular species and were individually maximized for each compound. The parent and daughter ions for monitoring the target oxylipin and the corresponding parameters are presented in Supplementary Table S2. The plasma ratio of epoxyeicosatrienoic acids to dihydroxyeicosatrienoic acids was calculated for each individual animal.

Results
Sorafenib Inhibits Soluble Epoxide Hydrolase, but This Inhibitory Activity Does Not Affect Specific Kinases

Based on the structural similarity between sorafenib (3) and soluble epoxide hydrolase inhibitors (Fig. 1; ref. 29), we suspected that sorafenib might be a soluble epoxide hydrolase inhibitor. To test this hypothesis, we first measured the inhibition potency (IC\textsubscript{50}) of sorafenib with the recombinant affinity purified human and murine soluble epoxide hydrolases using a fluorescent assay. As shown in Table 1, we found an IC\textsubscript{50} for sorafenib of 12 nmol/L for the human and 30 for the murine soluble epoxide hydrolase enzymes, which is very similar to that of previously reported potent soluble epoxide hydrolase inhibitors, such as AUDA, t-AUCB, TPAU, or TUPS (31–33). Interestingly, sunitinib and dasatinib, other VEGF receptor and multikinase inhibitor, respectively (2), are not potent inhibitors of the human soluble epoxide hydrolase. To define the potency of sorafenib as a soluble epoxide hydrolase inhibitor, we determined its dissociation constant (K\textsubscript{D}; see Fig. 2) using a radioactivity-based assay. Sorafenib has a K\textsubscript{D} of 17 nmol/L, which is ∼10-fold higher than that of the very potent t-AUCB but similar to the K\textsubscript{D} of other potent soluble epoxide hydrolase inhibitors.

Figure 5. Conventional soluble epoxide hydrolase inhibitors of varying potency do not alter cell growth or apoptosis. ACHN and A498 cells were incubated with serum-free quiescence media for 18 h and then treated with 10% serum-containing media containing vehicle (DMSO; 1 μL/mL), sorafenib (10 μmol/L), and indicated soluble epoxide hydrolase inhibitors (10 μmol/L) for an additional 48 h. A, an MTT assay was done as described in Materials and Methods. The visible absorbance of each well was quantified using a microplate reader. B, an assay of caspase-1 and caspase-3 activity was assessed as described in Materials and Methods. The visible absorbance of each well was quantified using a microplate reader.

Figure 6. Neither sorafenib nor sunitinib synergizes with soluble epoxide hydrolase inhibitors on cell survival. A, ACHN and A498 cells were treated as described in Fig. 5 with the soluble epoxide hydrolase inhibitors AUBA and t-AUCB (50 μmol/L) in the presence of vehicle (DMSO), sorafenib (5 μmol/L), or sunitinib (0.5 μmol/L). B, ACHN cells were treated as in A. Epoxyeicosatrienic acids or DMSO vehicle was added to the wells at 10 μmol/L. After 48 h, the MTT assay was done as described in Materials and Methods. The visible absorbance of each well was quantified using a microplate reader.
In addition to the soluble epoxide hydrolase inhibitory activity described above, sorafenib has well-established inhibitory activity against several kinases, including Raf, mitogen-activated protein kinase/ERK, and VEGF receptor, which by conventional wisdom accounts for its potent anti-proliferative and antiangiogenic effects in vivo (36–38). Thus, we sought to determine whether soluble epoxide hydrolase inhibitors acted on several oncogenically relevant kinases. Although sorafenib and the MEK inhibitor PD98059 (as control) attenuate ERK phosphorylation as expected in two renal cell carcinoma cell lines, five soluble epoxide hydrolase inhibitors selected because of their varied IC50s (Table 1) do not decrease ERK phosphorylation at a similar concentration (Fig. 4A and B). In addition, although sorafenib attenuates phospho-VEGF and causes apoptosis as is evidenced by PARP cleavage, there was no effect by three soluble epoxide hydrolase inhibitors with widely variable structures, KIS, and IC50s on these properties (Fig. 4C).

The Soluble Epoxide Hydrolase Inhibitors Do Not Cause Growth Inhibition or Apoptosis and Do Not Synergize with Sorafenib

Sorafenib is known to decrease cell growth and tumor vascularization and induce apoptosis; all of these are presumed mechanisms of the therapeutic effect of sorafenib in kidney cancer (39). We next asked whether the soluble epoxide hydrolase inhibitory activity of sorafenib accounts for its apoptosis or growth inhibitory effects in renal cell carcinoma cells. We used the MTT assay to assess cell growth and an assay of caspase-3 activity to measure apoptosis. Both renal cell carcinoma cell lines were incubated with sorafenib or five soluble epoxide hydrolase inhibitors for 48 hours. Although sorafenib markedly decreased cell growth (by 65–70% as compared with serum-stimulated cells), the effect of the soluble epoxide hydrolase inhibitors on cell growth was quite variable and considerably less pronounced (Fig. 5A). Furthermore, cell growth was reduced more with the weaker soluble epoxide hydrolase inhibitors, suggesting that the soluble epoxide hydrolase inhibitory activity does not correspond to renal cell carcinoma cell viability (r2 < 0.10 between cell viability and inhibition potency). Sorafenib incubation also resulted in apoptosis as evidenced by activation of caspase-1 and caspase-3 activity, as expected, whereas there was no consistent such effect with the soluble epoxide hydrolase inhibitors (Fig. 5B).

If the intrinsic soluble epoxide hydrolase inhibitory activity of sorafenib contributes to its proapoptotic activity, it would be expected that soluble epoxide hydrolase inhibitors would synergize with sorafenib with respect to this property. To examine this possibility, both renal cell carcinoma cell lines were incubated with sorafenib alone, sunitinib alone (which has anti-VEGF and anti-raf activity but not soluble epoxide hydrolase inhibitory activity; see Table 1), or with one of two soluble epoxide hydrolase inhibitors having disparate IC50s; these cells were subjected to an MTT assay (Fig. 6A). The experiment was repeated with the addition of exogenous epoxyeicosatrienoic acids, the substrate for soluble epoxide hydrolase (Fig. 6B). Consistent with the data described above, both soluble epoxide hydrolase inhibitors TPAU and TUPS seem relatively less potent when determining KIs with a radioactive assay than determining IC50s with a fluorescent assay. Such discrepancy has been observed before (26).

Because sorafenib showed good inhibitory activity against soluble epoxide hydrolase, we next sought to understand how it binds to this enzyme. Sorafenib was manually docked at the active site of the human soluble epoxide hydrolase using an X-ray structure previously published (Fig. 3; ref. 29). Sorafenib was noted to be bound through H-bonding interactions with the residues Tyr381, Tyr465, and Asp333 as observed for other urea-based inhibitors (34, 35). However, unlike t-AUCB, sorafenib did not establish a hydrogen bond with Met418 (33). The lack of this H-bonding could explain the slightly decreased inhibitory activity of sorafenib compared with t-AUCB. Conversely, t-AUCB and other soluble epoxide hydrolase inhibitors were manually docked at the active site of the B-Raf X-ray structure (3). Interestingly, the latter compounds were able to bind by making favorable H-bonds with the urea groups in t-AUCB as does sorafenib, without any unfavorable interactions with other residues at the active site (data not shown), suggesting that soluble epoxide hydrolase inhibitors could inhibit B-Raf and other kinases. However, the soluble epoxide hydrolase inhibitors studied here only show the urea interaction observed between sorafenib and B-Raf (3) and not the additional favorable interactions between sorafenib and B-Raf used to explain the tight binding of sorafenib with the target kinase. Thus, there seems to be different structure-activity relationships between the soluble epoxide hydrolase inhibitors and kinase inhibitors with sorafenib being somewhat unique in being a potent inhibitor of both enzymes. The structures of many soluble epoxide hydrolase inhibitors are close enough to sorafenib that a cautious approach with inhibitor design suggests screening possible soluble epoxide hydrolase inhibitors against a library of kinases.
inhibitors and both raf/VEGF inhibitors had apoptosis-inducing activity (the latter of a higher magnitude than the former), but there was no synergistic effect when the raf/VEGF inhibitors and soluble epoxide hydrolase inhibitors were added together to the cells in the presence and absence of exogenous epoxyeicosatrienoic acids. Thus, it is unlikely that the soluble epoxide hydrolase inhibitor activity inherent in sorafenib is contributing substantially to sorafenib-induced apoptosis.

Sorafenib Displays the Oxylipid Profiles of Soluble Epoxide Hydrolase Inhibition and Is Anti-inflammatory In vivo

Published data from our group have shown that soluble epoxide hydrolase inhibitors possess marked anti-inflammatory activity in an LPS-challenged mouse model of acute inflammation (21). To determine whether sorafenib possesses similar anti-inflammatory activity, which may be due to its soluble epoxide hydrolase inhibitor property, we first examined the pharmacokinetics of sorafenib tosylate in a murine model by oral administration at 5 mg/kg. Blood levels of sorafenib reached the maximum concentration ($C_{\text{max}}$) of $\sim 120$ nmol/L 2 hours after administration, and then slowly decrease such that no sorafenib could be detected after 24 hours (Fig. 7). In this system, one-compartmental analysis was shown to be the best fit model. We calculated an area under the concentration-time course curve (AUC)0-24 of 630 nmol/L h, and an elimination half-life of 2.6 hours for sorafenib. The sorafenib pharmacokinetic profile is compared with that of $t$-AUCB used at a roughly 5× lower concentrations because of its high potency (Fig. 7). The soluble epoxide hydrolase inhibitor $t$-AUCB afforded a larger AUC0-24 of 2,580 nmol/L h and a longer elimination half-life of >24 hours at an oral dose of 1 mg/kg (30). The compounds showed AUC0-24/$IC_{50}$ (an estimate of exposure and potency) of 21 and 645 for sorafenib and $t$-AUCB, respectively. Sorafenib and $t$-AUCB had blood levels above their murine $IC_{50}$s for 8 and 24 hours, respectively. Compared with the results from murine model, sorafenib in man provides a higher $C_{\text{max}}$ (>1,500 nmol/L), later T$\text{max}$ (>2 hours), longer elimination half-life (>20 hours), larger AUC0-12 (>13,000 nmol/L h), and larger AUC0-12/$IC_{50}$ (>1,080) in its phase I study even at the similar doses (40, 41).

To confirm that sorafenib inhibits soluble epoxide hydrolase in vivo, the epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids were measured by liquid chromatography-mass spectrometry/mass spectrometry in plasma samples taken 24 hours after treatment with LPS and then sorafenib. The termination time (24 hours) was established by a time-dependent study on sorafenib reversing the LPS-challenged hypotension. The plasma ratio of epoxyeicosatrienoic acids to dihydroxyeicosatrienoic acids characterizes the soluble epoxide hydrolase inhibition. Upon LPS challenge, the production of epoxyeicosatrienoic acids dramatically decreased as compared with nontreated animals, resulting in a significant decrease in the plasma ratio of epoxyeicosatrienoic acids to dihydroxyeicosatrienoic acids (Fig. 8A and B). Sorafenib inhibited the production of dihydroxyeicosatrienoic acids, reversing the ratio of

<table>
<thead>
<tr>
<th>Treatments</th>
<th>LPS (mg/kg)</th>
<th>Sarafenib (μmol/kg)</th>
<th>Sunitinib (μmol/kg)</th>
<th>$t$-AUCB (μmol/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>-</td>
<td>30</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>10</td>
<td>-</td>
<td>30</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>10</td>
<td>10</td>
<td>30</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>10</td>
<td>10</td>
<td>30</td>
<td>-</td>
<td>2.5</td>
</tr>
</tbody>
</table>

* significantly different ($P < 0.05$) from normal control; $\dagger$ significantly different ($P < 0.05$) from LPS control; $^\dagger$ significantly different ($P < 0.05$) from the mice receiving LPS and sorafenib determined by ANOVA followed with Tukey’s or Games-Howell’s test.
epoxyeicosatrienioic acids to dihydroxyeicosatrienioic acids to normal level. Administration of sorafenib alone inhibited the production of dihydroxyeicosatrienioic acids, resulting in a dramatic increase in the plasma ratio of epoxyeicosatrienioic acids to dihydroxyeicosatrienioic acids. As a control, administration of the soluble epoxide hydrolase inhibitor t-AUCB increased the production of epoxyeicosatrienioic acids, resulting in an increase in the ratio of epoxyeicosatrienioic acids to dihydroxyeicosatrienioic acids, as expected. Sunitinib, which does not possess soluble epoxide hydrolase inhibitory activity (see Table 1), inhibits the production of epoxyeicosatrienioic acids and dihydroxyeicosatrienioic acids, resulting in a decrease in the ratio of epoxyeicosatrienioic acids to dihydroxyeicosatrienioic acids. Thus, administration of sorafenib but not sunitinib to mice has the oxyxylipid signature of soluble epoxide hydrolase inhibition, consistent with the in vitro data described earlier.

As discussed above, soluble epoxide hydrolase inhibition has been shown to be anti-inflammatory in an LPS-challenged murine hypotension model (21), yet it would not be expected that kinase inhibition (as from sorafenib) would have a similar global effect (42). To determine whether sorafenib has a salutary effect on LPS-induced hypotension, we treated LPS-challenged mice with sorafenib. Although the soluble epoxide hydrolase inhibitor t-AUCB at 2.5 μmol/kg attenuates the hypotensive response of LPS to some degree, LPS-induced hypotension was completely reversed with sorafenib treatment (Fig. 8C), suggesting that soluble epoxide hydrolase inhibition accounts for at least part of the anti-inflammatory effect of sorafenib. Sunitinib attenuated the LPS-induced hypotensive effect to a smaller degree. However, the reduction in hypotension and the alteration in oxyxylipin profiles by sunitinib are much greater than that can be accounted for by its negligible soluble epoxide hydrolase inhibition, suggesting more complex mechanisms of action.

**Discussion**

The treatment of kidney cancer has been revolutionized by the appearance and surprising efficacy of the multikinase inhibitors sorafenib and sunitinib in heretofore chemotherapy-resistant malignancies (1). Although these drugs target many tyrosine kinases, given the high degree of angiogenesis accompanying kidney cancer, the VEGF receptor tyrosine kinase is likely the most important target of these agents in this disease. This physiology is dictated by the constitutive activation of the hypoxia-inducible factor pathway seen frequently in kidney cancer (43). However, although the VEGF receptor inhibitors possess important salutary effects on the malignancies targeted, there exist serious adverse effects associated with these treatments, most likely because of the fact that VEGF is necessary for vascular homeostasis (44). Thus, it is important to investigate other properties of the VEGF receptor inhibitors and thereby tease out mechanistic differences, which can be exploited in future refinement of this therapeutic paradigm. In this study, we have used modeling of the crystal structures to identify an unexpected property of sorafenib that begs further investigation.

Docking studies with murine and human soluble epoxide hydrolase indicated that sorafenib but not several other kinase inhibitors should be a potent inhibitor of the enzyme. Docking of several soluble epoxide hydrolase inhibitors in the B-Raf kinase catalytic site failed to show adverse interactions, cautioning that soluble epoxide hydrolase inhibitors should be screened on kinase libraries. However, the soluble epoxide hydrolase inhibitors docked failed to show the favorable interactions thought to result in the potent inhibition of sorafenib of some kinases (3). As predicted from docking studies, we showed that sorafenib but not sunitinib causes inhibition of the soluble epoxide hydrolase with the potency similar to the best available soluble epoxide hydrolase inhibitors, although these soluble epoxide hydrolase inhibitors failed to inhibit the kinases studied. This soluble epoxide hydrolase inhibition, which is likely unique among the VEGF receptor and raf inhibitors, increases the serum and/or tissue levels of epoxyeicosatrienioic acid and affects other lipid mediators that are known to have a variety of clinical effects, including the reduction of inflammation and hypertension. Although all of the ramifications of this finding have not yet been worked out, it is clear from previous work in our and other laboratories that soluble epoxide hydrolase inhibition leads to varied consequences. In the case of treatment of cancers, many of which are now considered inflammatory diseases (45, 46), soluble epoxide hydrolase inhibition may be of benefit because of its anti-inflammatory properties (21).

There also is a caution that further attenuation of inflammation by soluble epoxide hydrolase inhibition, in the presence of standard immunosuppressive compounds sometimes used in chemotherapy, may make a patient more prone to overwhelming infection. However, even complete soluble epoxide hydrolase inhibition only increases epoxyeicosatrienioic acid levels several fold. Given the available data on soluble epoxide hydrolase inhibition and blood pressure (18, 47, 48), it is possible that the soluble epoxide hydrolase inhibitory property of sorafenib may ameliorate hypertension sometimes observed with kinase inhibitor therapy. In addition, the beneficial effects of soluble epoxide hydrolase inhibition in atherosclerosis (20) may lead to beneficial end-organ protection during sorafenib therapy, and the antinociceptive effects of soluble epoxide hydrolase inhibition (19) could add to the favorable effect profile of sorafenib in cancer patients.

Our finding that sorafenib fits into the active site of soluble epoxide hydrolase (Fig. 1) based on the X-ray crystal structures previously published (3, 29) was serendipitous. Despite targeting inhibition of VEGF receptor, the other kinase inhibitors dasatinib and sunitinib do not display soluble epoxide hydrolase inhibitory activity either in vitro or in vivo, as is evidenced by their decreased levels of blood pressure and cytokine modulation as compared with that of sorafenib. Along these lines, it is indeed provocative to consider that it is the soluble epoxide hydrolase inhibitory property of sorafenib that accounts for its differences from
Sorafenib Is an Inhibitor of Soluble Epoxide Hydrolase

In summary, we report a novel property of the VEGF receptor and Raf inhibitor sorafenib, which likely accounts for at least a substantial portion of its benefit and adverse effect profile. Further investigation, including in vivo studies, may lead to novel indications for this drug as explaining apparent benefits over other pharmaceuticals targeted kinases.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

References

22. Hiles JJ, Kolesar JM. Role of sunitinib and sorafenib in the treat-

23. Herrmann E, Bierer S, Gerss J, et al. Prospective comparison of sor-
afenib and sunitinib for second-line treatment of cytokine-refractory kid-

24. Wixtrom RN, Silva MH, Hammock BD. Affinity purification of cytosol-


37. Reganti S, Kabb E, Stock W, et al. Anti-angiogenic effects of sorafe-


45. Pollard JW. Tumour-educated macrophages promote tumour progres-


49. Ohbri JS, Patel TV, Humphreys BD. The case—progressive hyper-

50. Bhojani N, Jeldres C, Patard JJ, et al. Toxicities associated with the admininstration of sorafenib, sunitinib, and temsirolimus and their manage-


52. Wang Y, Wei X, Xiao X, et al. Arachidonic acid epoxygenase metabo-
lites stimulate endothelial cell growth and angiogenesis via mitogen-

53. Pozzi A, Macias-Perez I, Abari T, et al. Characterization of 5,6- and 8,9-epoxyeicosatrienoic acids (5,6- and 8,9-EET) as potent in vivo angio-